Lilly and Novo Nordisk Near White House Deal to Cut Obesity Drug Prices

Eli Lilly and Novo Nordisk are close to deals with the White House to lower prices of their obesity drugs, specifically for the lowest doses2 3 5.

The proposed price for the lowest dose of Lilly's Zepbound and Novo Nordisk's Wegovy is $149 per month, which is substantially less than current market prices2 3 5.

In exchange for lower prices, the drugs would gain coverage under Medicare—opening access to millions of Americans for weight loss (not just diabetes)2 4.

Details of these deals have not yet been finalized or publicly announced, but White House sources expect an announcement soon, possibly alongside pharmaceutical executives2 4.

The deals are part of a broader White House initiative (TrumpRx) pushing for lower prescription prices, utilizing direct negotiations and 'most-favored-nation' pricing strategies2.

If agreed, patients could access these drugs through a government-run website for $149/mo, with Medicaid and Medicare coverage anticipated1 2.

Lilly currently sells Zepbound at $349/mo for the lowest dose outside these negotiations4, indicating the deal could more than halve patient costs.

The initiative follows similar pricing deals by Pfizer and AstraZeneca to lower drug costs in the U.S. in exchange for increased coverage or tariff relief2.